Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 4;130(5):708-710.
doi: 10.1161/CIRCRESAHA.122.320799. Epub 2022 Mar 3.

GLP-1 (Glucagon-Like Peptide-1) Plays a Role in Carotid Chemoreceptor-Mediated Sympathoexcitation and Hypertension

Irving H Zucker  1 , Han-Jun Wang  2 , Harold D Schultz  1
Affiliations
Editorial

GLP-1 (Glucagon-Like Peptide-1) Plays a Role in Carotid Chemoreceptor-Mediated Sympathoexcitation and Hypertension

Irving H Zucker et al. Circ Res. .
No abstract available

Keywords: Editorials; GI peptides; chemoreflex; high blood pressure; hypoxia; sympathetic nerve activity.

PubMed Disclaimer

Figures

Figure:
Figure:
The gastrointestinal peptide GLP-1 is released from L-type epithelial cells in response to hyperglycemia. GLP-1 may induce several affects at various sites including enhancement of insulin release by beta cells in the pancreas and by activation of the GLP-1R on glomus cells in the carotid body. Insulin possesses sympatho-excitatory effects itself. In addition to circulating GLP-1, it appears that GLP-1 is contained in afferent carotid body. Activation through the GLP-1R reduces sympathetic outflow in a genetic model of hypertension. Therefore, abnormalities in this pathway (i.e. reduced activation or activity of the GLP-1R) may contribute to the pathogenesis of hypertension. (Figure made with BioRender.com).
See this image and copyright information in PMC

Comment on

  • GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition.
    Pauza AG, Thakkar P, Tasic T, Felippe I, Bishop P, Greenwood MP, Rysevaite-Kyguoliene K, Ast J, Broichhagen J, Hodson DJ, Salgado HC, Pauza DH, Japundzic-Zigon N, Paton JFR, Murphy D. Pauza AG, et al. Circ Res. 2022 Mar 4;130(5):694-707. doi: 10.1161/CIRCRESAHA.121.319874. Epub 2022 Feb 1. Circ Res. 2022. PMID: 35100822 Free PMC article.

References

    1. Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116:1007–1021. doi: 10.1161/circresaha.116.303596 - DOI - PubMed
    1. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804–1814. doi: 10.1161/circresaha.114.302524 - DOI - PubMed
    1. Abdala AP, McBryde FD, Marina N, Hendy EB, Engelman ZJ, Fudim M, Sobotka PA, Gourine AV, Paton JF. Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. J Physiol. 2012;590:4269–4277. doi: 10.1113/jphysiol.2012.237800 - DOI - PMC - PubMed
    1. Del Rio R, Marcus NJ, Schultz HD. Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function. J Am Coll Cardiol. 2013;62:2422–2430. doi: 10.1016/j.jacc.2013.07.079 - DOI - PMC - PubMed
    1. Iturriaga R, Alcayaga J, Chapleau MW, Somers VK. Carotid body chemoreceptors: physiology, pathology, and implications for health and disease. Physiol Rev. 2021;101:1177–1235. doi: 10.1152/physrev.00039.2019 - DOI - PMC - PubMed

Substances